162 related articles for article (PubMed ID: 37148657)
1. Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.
Fitzel R; Secker-Grob KA; Keppeler H; Korkmaz F; Schairer R; Erkner E; Schneidawind D; Lengerke C; Hentrich T; Schulze-Hentrich JM; Schneidawind C
Neoplasia; 2023 Jul; 41():100902. PubMed ID: 37148657
[TBL] [Abstract][Full Text] [Related]
2. MAT2A as Key Regulator and Therapeutic Target in
Secker KA; Bloechl B; Keppeler H; Duerr-Stoerzer S; Schmid H; Schneidawind D; Jeong J; Hentrich T; Schulze-Hentrich JM; Schneidawind C
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456310
[TBL] [Abstract][Full Text] [Related]
3. Uncovering NOTCH1 as a Promising Target in the Treatment of
Fischer J; Erkner E; Fitzel R; Radszuweit P; Keppeler H; Korkmaz F; Roti G; Lengerke C; Schneidawind D; Schneidawind C
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833915
[No Abstract] [Full Text] [Related]
4. Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9.
Secker KA; Keppeler H; Duerr-Stoerzer S; Schmid H; Schneidawind D; Hentrich T; Schulze-Hentrich JM; Mankel B; Fend F; Schneidawind C
Oncogene; 2019 Nov; 38(46):7181-7195. PubMed ID: 31417187
[TBL] [Abstract][Full Text] [Related]
5. Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia.
Tejedor JR; Bueno C; Vinyoles M; Petazzi P; Agraz-Doblas A; Cobo I; Torres-Ruiz R; Bayón GF; Pérez RF; López-Tamargo S; Gutierrez-Agüera F; Santamarina-Ojeda P; Ramírez-Orellana M; Bardini M; Cazzaniga G; Ballerini P; Schneider P; Stam RW; Varela I; Fraga MF; Fernández AF; Menéndez P
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 33983906
[TBL] [Abstract][Full Text] [Related]
6. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
7. CRISPR Gene Editing of Murine Blood Stem and Progenitor Cells Induces MLL-AF9 Chromosomal Translocation and MLL-AF9 Leukaemogenesis.
Sarrou E; Richmond L; Carmody RJ; Gibson B; Keeshan K
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32549410
[TBL] [Abstract][Full Text] [Related]
8. Targeting epigenetic programs in MLL-rearranged leukemias.
Bernt KM; Armstrong SA
Hematology Am Soc Hematol Educ Program; 2011; 2011():354-60. PubMed ID: 22160057
[TBL] [Abstract][Full Text] [Related]
9. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
Lopez-Millan B; Sanchéz-Martínez D; Roca-Ho H; Gutiérrez-Agüera F; Molina O; Diaz de la Guardia R; Torres-Ruiz R; Fuster JL; Ballerini P; Suessbier U; Nombela-Arrieta C; Bueno C; Menéndez P
Leukemia; 2019 Jul; 33(7):1557-1569. PubMed ID: 30635633
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting potential of chromatin-associated proteins in MLL-rearranged acute leukemia.
Xu X; Schneider B
Cell Oncol (Dordr); 2019 Apr; 42(2):117-130. PubMed ID: 30446944
[TBL] [Abstract][Full Text] [Related]
11. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
[TBL] [Abstract][Full Text] [Related]
12. Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen.
Zhang H; Zhang Y; Zhou X; Wright S; Hyle J; Zhao L; An J; Zhao X; Shao Y; Xu B; Lee HM; Chen T; Zhou Y; Chen X; Lu R; Li C
Elife; 2020 Oct; 9():. PubMed ID: 33001025
[TBL] [Abstract][Full Text] [Related]
13. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
14. High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells.
Jeong J; Jager A; Domizi P; Pavel-Dinu M; Gojenola L; Iwasaki M; Wei MC; Pan F; Zehnder JL; Porteus MH; Davis KL; Cleary ML
Blood Adv; 2019 Oct; 3(19):2825-2835. PubMed ID: 31582391
[TBL] [Abstract][Full Text] [Related]
15. JMJD1C-regulated lipid synthesis contributes to the maintenance of
Qi D; Wang J; Zhao Y; Yang Y; Wang Y; Wang H; Wang L; Wang Z; Xu X; Hu Z
Leuk Lymphoma; 2022 Sep; 63(9):2149-2160. PubMed ID: 35468015
[No Abstract] [Full Text] [Related]
16. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik S; Liu Q; Tansey WP
Elife; 2024 Apr; 12():. PubMed ID: 38682900
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
Chen L; Sun Y; Wang J; Jiang H; Muntean AG
Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
[TBL] [Abstract][Full Text] [Related]
18. Disordered epigenetic regulation in MLL-related leukemia.
Zhang Y; Chen A; Yan XM; Huang G
Int J Hematol; 2012 Oct; 96(4):428-37. PubMed ID: 23054645
[TBL] [Abstract][Full Text] [Related]
19. SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.
Dong Y; Zhao X; Feng X; Zhou Y; Yan X; Zhang Y; Bu J; Zhan D; Hayashi Y; Zhang Y; Xu Z; Huang R; Wang J; Zhao T; Xiao Z; Ju Z; Andreassen PR; Wang QF; Chen W; Huang G
Leukemia; 2019 Nov; 33(11):2585-2598. PubMed ID: 30967619
[TBL] [Abstract][Full Text] [Related]
20. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.
Geng H; Brennan S; Milne TA; Chen WY; Li Y; Hurtz C; Kweon SM; Zickl L; Shojaee S; Neuberg D; Huang C; Biswas D; Xin Y; Racevskis J; Ketterling RP; Luger SM; Lazarus H; Tallman MS; Rowe JM; Litzow MR; Guzman ML; Allis CD; Roeder RG; Müschen M; Paietta E; Elemento O; Melnick AM
Cancer Discov; 2012 Nov; 2(11):1004-23. PubMed ID: 23107779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
